Phase I Dose-Escalation Pharmacokinetics of AZT-P-ddI (IVX-E-59) in Patients with Human Immunodeficiency Virus.

MLA

Zhou, Xiao-Jian, et al. “Phase I Dose-Escalation Pharmacokinetics of AZT-P-DdI (IVX-E-59) in Patients with Human Immunodeficiency Virus.” Journal of Clinical Pharmacology, vol. 37, no. 3, Mar. 1997, pp. 201–13. EBSCOhost, https://doi.org/10.1002/j.1552-4604.1997.tb04782.x.

APA

Zhou, X.-J., Squires, K., Pan-Zhou, X.-R., Bernhard, S., Agrofoglio, L., Kirk, M., Duchin, K. L., & Sommadossi, J.-P. (1997). Phase I Dose-Escalation Pharmacokinetics of AZT-P-ddI (IVX-E-59) in Patients with Human Immunodeficiency Virus. Journal of Clinical Pharmacology, 37(3), 201–213. https://doi.org/10.1002/j.1552-4604.1997.tb04782.x

Chicago

Zhou, Xiao-Jian, Kathleen Squires, Xin-Ru Pan-Zhou, Steve Bernhard, Luigi Agrofoglio, Marion Kirk, Kenneth L. Duchin, and Jean-Pierre Sommadossi. 1997. “Phase I Dose-Escalation Pharmacokinetics of AZT-P-DdI (IVX-E-59) in Patients with Human Immunodeficiency Virus.” Journal of Clinical Pharmacology 37 (3): 201–13. doi:10.1002/j.1552-4604.1997.tb04782.x.